Genome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRIT

Schizophrenia Research

Volumn 164, Issue 1-3, 2015, Pages 181-186

  Docherty, Anna R ^a   Bigdeli, T Bernard ^a   Edwards, Alexis C ^a   Bacanu, Silviu ^a   Lee, Donghyung ^a   Neale, Michael C ^a   Wormley, Brandon K ^a   Walsh, Dermot ^b   O'Neill, F Anthony ^c   Riley, Brien P ^a   Kendler, Kenneth S ^a   Fanous, Ayman H ^a,d,e  

^a Department of General Services   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c Center for Public Health   (Ireland)

^d Washington Veterans Affairs Healthcare System   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dimensional assessment; Gene enrichment; Gene pathway; Genetic; Modifier gene; OPCRIT; Schizophrenia; Symptoms

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CYCLIC GMP;

ARTICLE; DEPRESSION; FACTORIAL ANALYSIS; GENE; GENE ONTOLOGY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IRISH (CITIZEN); MAJOR CLINICAL STUDY; MANIA; MENTAL DISEASE ASSESSMENT; OPERATIONAL CRITERIA CHECKLIST FOR PSYCHOTIC DISORDERS; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; PTPRG GENE; SCHIZOPHRENIA; WBP1L GENE; COMPLICATION; FACTOR ANALYSIS; FEMALE; GENE REGULATORY NETWORK; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MALE; PSYCHOTIC DISORDERS; SINGLE NUCLEOTIDE POLYMORPHISM;

FACTOR ANALYSIS, STATISTICAL; FEMALE; GENE REGULATORY NETWORKS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84929278460     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.02.013     Document Type: Article

References (45)

1. Abecasis G.R., Cherny S.S., Cookson W.O., Cardon L.R. Merlin-rapid analysis of dense genetic maps using sparse gene flow trees. Nat. Genet. 2002, 30(1):97-101.
2. Andreassen O.A., Djurovic S., Thompson W.K., Schork A.J., Kendler K.S., et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am. J. Hum. Genet. 2013, 92(2):197-209.
3. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25(1):1-27.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 1995, 57(1):289-300.
5. Bigdeli T.B., Bacanu S.A., Webb B.T., Walsh D., O'Neill F.A., et al. Molecular validation of the schizophrenia spectrum. Schizophr. Bull. 2014, 40:60-65.
6. Bleuler E. Dementia Praecox or the Group of Schizophrenias 1950, International Universities Press, New York, NY.
7. Brisch R., Saniotis A., Wolf R., Bielau H., Bernstein H.G., et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front. Psychiatry 2014, 5:47.
8. Chen W.M., Abecasis G.R. Family-based association tests for genomewide association scans. Am. J. Hum. Genet. 2007, 81(5):913-926.
9. Chen X., Lee G., Maher B.S., Fanous A.H., Chen J., et al. GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Mol. Psychiatry 2011, 16(11):1117-1129.
10. Cohen B.M., Yurgelun-Todd D., English C.D., Renshaw P.F. Abnormalities of regional distribution of cerebral vasculature in schizophrenia detected by dynamic susceptibility contrast MRI. Am. J. Psychiatry 1995, 152(12):1801-1803.
11. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 2006, 26(4-6):365-384.
12. Curtis C.E., Iacono W.G., Beiser M. Relationship between nailfold plexus visibility and clinical, neuropsychological, and brain structural measures in schizophrenia. Biol. Psychiatry 1999, 46(1):102-109.
13. Derks E.M., Vorstman J.A., Ripke S., Kahn R.S., Schizophrenia Psychiatric Genomic C., et al. Investigation of the genetic association between quantitative measures of psychosis and schizophrenia: a polygenic risk score analysis. PLoS One 2012, 7(6):e37852.
14. Fanous A.H., Neale M.C., Webb B.T., Straub R.E., O'Neill F.A., et al. Novel linkage to chromosome 20p using latent classes of psychotic illness in 270 Irish high-density families. Biol. Psychiatry 2008, 64(2):121-127.
15. Fanous A.H., Zhou B., Aggen S.H., Bergen S.E., Amdur R.L., et al. Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms. Am. J. Psychiatry 2012, 169(12):1309-1317.
16. Harris L.W., Wayland M., Lan M., Ryan M., Giger T., et al. The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS One 2008, 3(12):e3964.
17. Hennekens C.H., Hennekens A.R., Hollar D., Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 2005, 150(6):1115-1121.
18. Hudson C.J., Lin A., Cogan S., Cashman F., Warsh J.J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?. Biol. Psychiatry 1997, 41(5):507-513.
19. Insel T., Cuthbert B., Garvey M., Heinssen R., Pine D.S., et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 2010, 167(7):748-751.
20. Javitt D.C. Twenty-five years of glutamate in schizophrenia: are we there yet?. Schizophr. Bull. 2012, 38(5):911-913.
21. Javitt D.C., Schoepp D., Kalivas P.W., Volkow N.D., Zarate C., et al. Translating glutamate: from pathophysiology to treatment. Sci. Transl. Med. 2011, 3(102):102.
22. John B., Enright A.J., Aravin A., Tuschl T., Sander C., et al. Human microRNA targets. PLoS Biol. 2004, 2:e363.
23. Kamburov A., Stelzl U., Lehrach H., Herwig R. The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res. 2013, 41:D793-D800.
24. Kendler K.S., O'Neill F.A., Burke J., Murphy B., Duke F., et al. Irish study on high-density schizophrenia families: field methods and power to detect linkage. Am. J. Med. Genet. 1996, 67(2):179-190.
25. Kraepelin E. Dementia Praecox and Paraphrenia 1971, Krieger, New York, (first published, 1919.).
26. Krek A., Grun D., Poy M.N., Wolf R., Rosenberg L., et al. Combinatorial microRNA target predictions. Nat. Genet. 2005, 37:495-500.
27. Lewis S. Synaptic physiology: it takes two for NMDA receptors. Nat. Rev. Neurosci. 2012, 13(10):666-667.
28. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
29. Li M.X., Kwan J.S., Sham P.C. HYST: a hybrid set-based test for genome-wide association studies, with application to protein-protein interaction-based association analysis. Am. J. Hum. Genet. 2012, 91:478-488.
30. Lien Y.J., Huang S.S., Liu C.M., Hwu H.G., Faraone S.V., et al. A genome-wide quantitative linkage scan of niacin skin flush response in families with schizophrenia. Schizophr. Bull. 2013, 39(1):68-76.
31. McGuffin P., Farmer A., Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch. Gen. Psychiatry 1991, 48:764-770.
32. Meier M.H., Caspi A., Reichenberg A., Keefe R.S., Fisher H.L., et al. Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. Am. J. Psychiatry 2014, 171(1):91-101.
33. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
34. Purcell S.M., Moran J.L., Fromer M., Ruderfer D., Solovieff N., et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014, 506(7487):185-190.
35. Rado S. Dynamics and classification of disordered behavior. Am. J. Psychiatry 1953, 110:406-426.
36. Raiche G., Magis D. nFactors Package for Parallel Analysis and Non Graphical Solutions to the Cattell Scree Test, Version 2.3.3. 2010, Maintainer: raiche.gillesatuqam.ca.
37. Ripke S., O'Dushlaine C., Chambert K., Moran J.L., Kahler A.K., Akterin S., Bergen S.E., Collins A.L., Crowley J.J., Fromer M., Kim Y., Lee S.H., Magnusson P.K., Sanchez N., Stahl E.A., Williams S., Wray N.R., Xia K., Bettella F., Borglum A.D., Bulik-Sullivan B.K., Cormican P., Craddock N., de Leeuw C., Durmishi N., Gill M., Golimbet V., Hamshere M.L., Holmans P., Hougaard D.M., Kendler K.S., Lin K., Morris D.W., Mors O., Mortensen P.B., Neale B.M., O'Neill F.A., Owen M.J., Milovancevic M.P., Posthuma D., Powell J., Richards A.L., Riley B.P., Ruderfer D., Rujescu D., Sigurdsson E., Silagadze T., Smit A.B., Stefansson H., Steinberg S., Suvisaari J., Tosato S., Verhage M., Walters J.T., Multicenter Genetic Studies of Schizophrenia C., Levinson D.F., Gejman P.V., Kendler K.S., Laurent C., Mowry B.J., O'Donovan M.C., Owen M.J., Pulver A.E., Riley B.P., Schwab S.G., Wildenauer D.B., Dudbridge F., Holmans P., Shi J., Albus M., Alexander M., Campion D., Cohen D., Dikeos D., Duan J., Eichhammer P., Godard S., Hansen M., Lerer F.B., Liang K.Y., Maier W., Mallet J., Nertney D.A., Nestadt G., Norton N., O'Neill F.A., Papadimitriou G.N., Ribble R., Sanders A.R., Silverman J.M., Walsh D., Williams N.M., Wormley B., Psychosis Endophenotypes International C., Arranz M.J., Bakker S., Bender S., Bramon E., Collier D., Crespo-Facorro B., Hall J., Iyegbe C., Jablensky A., Kahn R.S., Kalaydjieva L., Lawrie S., Lewis C.M., Lin K., Linszen D.H., Mata I., McIntosh A., Murray R.M., Ophoff R.A., Powell J., Rujescu D., Van Os J., Walshe M., Weisbrod M., Wiersma D., Wellcome Trust Case Control C., Donnelly P., Barroso I., Blackwell J.M., Bramon E., Brown M.A., Casas J.P., Corvin A.P., Deloukas P., Duncanson A., Jankowski J., Markus H.S., Mathew C.G., Palmer C.N., Plomin R., Rautanen A., Sawcer S.J., Trembath R.C., Viswanathan A.C., Wood N.W., Spencer C.C., Band G., Bellenguez C., Freeman C., Hellenthal G., Giannoulatou E., Pirinen M., Pearson R.D., Strange A., Su Z., Vukcevic D., Donnelly P., Langford C., Hunt S.E., Edkins S., Gwilliam R., Blackburn H., Bumpstead S.J., Dronov S., Gillman M., Gray E., Hammond N., Jayakumar A., McCann O.T., Liddle J., Potter S.C., Ravindrarajah R., Ricketts M., Tashakkori-Ghanbaria A., Waller M.J., Weston P., Widaa S., Whittaker P., Barroso I., Deloukas P., Mathew C.G., Blackwell J.M., Brown M.A., Corvin A.P., McCarthy M.I., Spencer C.C., Bramon E., Corvin A.P., O'Donovan M.C., Stefansson K., Scolnick E., Purcell S., McCarroll S.A., Sklar P., Hultman C.M., Sullivan P.F. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 2013, 45(10):1150-1159.
38. Ruderfer D.M., Fanous A.H., Ripke S., McQuillin A., Amdur R.L., et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol. Psychiatry 2014, 19(9):1017-1024.
39. Schizophrenia Psychiatric Genome-Wide Association Study Consortium Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976.
40. Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511(7510):421-427.
41. Schmidt-Kastner R., van Os J., Schmitz C. Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. Schizophr. Res. 2006, 84(2-3):253-271.
42. Schmidt-Kastner R., van Os J., Esquivel G., Steinbusch H.W., Rutten B.P. An environmental analysis of genes associated with schizophrenia: hypoxia and vascular factors as interacting elements in the neurodevelopmental model. Mol. Psychiatry 2012, 17(12):1194-1205.
43. Vuchetich J.P., Liska J.L., Dionisio D.P., Stanwyck J.J., McGuire K.A., et al. Elevated nailfold plexus visibility aggregates in families and is associated with a specific negative symptom pattern in schizophrenia. Psychiatry Res. 2008, 160(1):30-37.
44. Ward P.E., Sutherland J., Glen E.M., Glen A.I. Niacin skin flush in schizophrenia: a preliminary report. Schizophr. Res. 1998, 29(3):269-274.
45. Wassef A., Baker J., Kochan L.D. GABA and schizophrenia: a review of basic science and clinical studies. J. Clin. Psychopharmacol. 2003, 23(6):601-640.